Last reviewed · How we verify
Mucinex® SE
Guaifenesin reduces mucus viscosity and promotes clearance of respiratory secretions to relieve chest congestion.
Guaifenesin reduces mucus viscosity and promotes clearance of respiratory secretions by increasing hydration of mucus. Used for Productive cough due to common cold, bronchitis, or other respiratory conditions.
At a glance
| Generic name | Mucinex® SE |
|---|---|
| Also known as | guaifenesin bi-layer tablet, Guaifenesin bi-layer tablet |
| Sponsor | Reckitt Benckiser Inc. |
| Drug class | Expectorant |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Cold & Cough |
| Phase | FDA-approved |
Mechanism of action
Guaifenesin is an expectorant that works by thinning mucus in the airways, making it easier to cough up and clear from the respiratory tract. This reduces the sensation of chest congestion and facilitates mucus drainage. Mucinex SE is an extended-release formulation designed to provide prolonged action over 12 hours.
Approved indications
- Productive cough due to bronchitis, common cold, or other respiratory conditions
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mucinex® SE CI brief — competitive landscape report
- Mucinex® SE updates RSS · CI watch RSS
- Reckitt Benckiser Inc. portfolio CI